Evaluation of long-acting insulin dose corresponding to lixisenatide dose in combination therapy of insulin and lixisenatide

Not Applicable

• Conditions: Type 2 diabetes mellitus

• Registration Number: JPRN-UMIN000012024
• Lead Sponsor: Kitano Hospital, The Tazuke Kofukai Medical Research Institute

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-10-11
• Study Completion: 2017-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Not provided

Exclusion Criteria

1. The patients who did not agree with this study 2. The patients with serious complications 3. The patients who are at high risk for hypoglycemia 4. The patients who have the history of severe hypoglycemia (needed an emergency transport according to the hypoglycemia unawareness) 5. Those who are not approved to be eligible to this study by corresponding researcher or co-researchers

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes in daily insulin dose of insulin glargine at 12 and 24 weeks

Secondary Outcome Measures

Name	Time	Method
Changes in blood glucose levels (average, SD value, MAGE value), HbA1c, body weight, and frequency of hypoglycemia at 4, 8, 12 and 24 weeks.